Temozolomid-Based Therapy in GEP-and Bronchopulmonary NEN from a Multicentric Study from Germany Abstract #1205

Introduction: Chemotherapy (CTx) with temozolomid as mono (TEM) or combination therapy with capcitabine (TEM/CAP) is a new cytotoxic regimen with good efficiency in pancreatic and bronchopulmonary NET-G1/G2 and NEC-G3.
Aim(s): Therefore TEM-based CTx was analyzed in a multicentric study from the German NET-registry
Materials and methods: Patients (pts.) diagnosed since 1988 and treated with TEM or TEM/CAP were included, using SPSS 19.0 for analysis.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Sebastian Maasberg

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1200 Clinical Outcome of Everolimus Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Data from the German NET-Register
Introduction: Everolimus (EVE) has importantly impacted the treatment (Tx) of mostly pancreatic NEN.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Sebastian Maasberg
Authors: Pape U F, Bacher M, Fottner C, Lahner H, ...
Keywords: everolimus, outcome
#1201 Results of Sunitinib Treatment of Advanced Neuroendocrine Neoplasms: “Real-life” Outcome Data from the German NET-Register
Introduction: Among modern treatments (Tx) for neuroendocrine neoplasms (NEN) sunitinib (SUN) has impacted Tx of primarily pancreatic NEN (pNEN).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Sebastian Maasberg
Keywords: sunitinib, outcome
#1554 Combination of Lanreotide Autogel and Temozolomide in Patients with Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) - A Pilot-Study
Introduction: Therapeutic options for patients with advanced progressive GEP-NET are still limited.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Prof. Dr. Markus Raderer
Authors: Raderer M, Hörsch D, Lahner H, Rinke A, ...
#449 Effective Treatment of a Metastatic Thymic Neuroendocrine Tumor with Capecitabine and Temozolomide: A Case Report
Introduction: Thymic neuroendocrine tumors are rare, with an estimated annual incidence of 0.2 per million. They are generally considered chemoresistant and there have been no reported cases of an objective response to therapy.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Vita SarangaPerry
#709 Temozolomide and Capecitabine: An Effective Combination in Metastasic G2 NETs
Introduction: Treatment of neuroendocrine tumors (NETs) with chemotherapy has been validated in different studies. Recently a retrospective trial demonstrated high and durable response rate with Temozolomide and Capecitabine in 30 pancreatic NETs (pNETs).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: María Jesús Barrio